Monte Rosa Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| GLUE | KYMR | CCCC | ARVN | ONCO.ST | NRIX | |
|---|---|---|---|---|---|---|
| Market cap | 923.09M | 11.63B | 383.84M | 486.01M | 746.25M | 1.74B |
| P/E (TTM) | — | — | — | — | — | 6.6 |
| Forward P/E | -5.9 | -27.1 | -3.4 | -2.3 | -2.4 | -12.5 |
| Price/book | 1.9 | 7.2 | 1.6 | 0.9 | 27.5 | 1.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −15.43% | +112.21% | +35.44% | −25.91% | −66.03% | +107.31% |
| Today | +3.94% | +7.21% | −2.80% | +4.65% | +0.35% | −38.23% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All GLUE news ›What GPT-Rosalind-6 Means for Biology Research
The research deployment shares GPT-6 Astra’s weights; its test scores cover specific tasks, and access runs through approved Work and Codex accounts. GPT-Rosalind-6 uses GPT-6 Astra’s weights, with no additional training data or…
Monte Rosa Therapeutics, Inc. Stock (GLUE) - Quote Nasdaq
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein…
Monte Rosa Therapeutics Says MRT-8102 Showed Biomarker Improvements in Phase 1 Study
Monte Rosa Therapeutics said Thursday its experimental drug, MRT-8102, achieved its phase 1 study objectives, showing strong NEK7 degradation and reductions in multiple biomarkers associated with... Monte Rosa Therapeutics, Inc.…
Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating
Price: 15.68, Change: -7.00, Percent Change: -30.86 ... Monte Rosa Therapeutics, Inc. Biotechnology & Medical Research Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating Published on…
Targeting the Root Causes of Coronary Stent Restenosis: New Mechanism-Guided Approaches
ISR remains a significant challenge in cardiovascular medicine, prompting a shift toward mechanism-guided therapies that address the biological heterogeneity of restenosis. The trajectory of ISR management is therefore moving away from a…
Same Drug, Different Cells: Why mTOR Inhibition in Plaques Defies Simple Rules
A new review argues that mTOR's effects in atherosclerotic plaques depend on cell state, plaque niche, signalling complex and drug exposure duration, and that plaque-targeted rapalog delivery remains a testable framework rather than an…
Comparing Emergent Biosolutions (NYSE:EBS) & Monte Rosa Therapeutics (NASDAQ:GLUE)
Posted by Kim Johansen on Oct 21st, 2026 Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) and Emergent Biosolutions (NYSE:EBS – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will…
Investors Buy Large Volume of Monte Rosa Therapeutics Call Options (NASDAQ:GLUE)
Posted by Sarita Garza on Oct 19th, 2026 Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Free Report) was the target of some unusual options trading activity on Monday. Traders purchased 2,011 call options on the stock. This represents an…
AI-designed molecular glue degrader ISM9546 targets VAV1 for autoimmune disease treatment
The nomination of ISM9546 arrives at a moment when the field of targeted protein degradation is moving well beyond its original scope.
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
Robust and sustained NEK7 degradation observed across 5 mg, 20 mg, and 40 mg once-daily dose levels, with similar biomarker reductions at all three doses HMGB1, calprotectin, S100A12, and SAA, damage-associated molecular patterns (DAMPs)…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com5
- themarketsdaily.com4
- marketbeat.com2
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.